Elite Pharmaceuticals Inc (OTCPK:ELTP)

Q3 2025 Elite Pharmaceuticals Inc Earnings Call Transcript

Feb 14, 2025 / 04:30 PM GMT

Release Date Price: $0.53 (-3.99%)

Transcript 8-K10-Q

Key Points

Positve

Elite Pharmaceuticals Inc (ELTP) reported a significant increase in year-to-date revenues, reaching $52 million, a 35% growth compared to the previous year.
The company successfully launched its generic lisdexamphetamine product, contributing to record-high revenues in January 2025.
Elite Pharmaceuticals Inc (ELTP) has a strong market share in amphetamine IR, commanding 17% of the market.
The company is in its best financial position ever, with strong fundamentals, low debt, and increasing working capital.
Elite Pharmaceuticals Inc (ELTP) is positioned for future growth with upcoming product launches and a focus on R&D.

Negative

Total revenues for the quarter decreased by 8% compared to the same quarter last year, primarily due to shipment delays.
R&D and GNA expenses increased significantly, with R&D up by 28% and GNA by 59%, impacting overall profitability.
The company faces challenges with DEA-imposed quotas on opioid sales, limiting potential revenue from these products.
Regulatory compliance costs have increased, adding to the company's operational expenses.
There are uncertainties regarding the launch timelines for some products due to regulatory and market conditions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ELTP.PK - Elite Pharmaceuticals Inc
Q3 2025 Elite Pharmaceuticals Inc Earnings Call
Feb 14, 2025 / 04:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and welcome to the Elite Pharmaceuticals conference call.

At this time, all lines have been placed on a listen-only mode.

Before management begins speaking, the conference has the following statements.

Elite would like to remind listeners that remarks made during this call may contain forward-looking statements that involve risks and uncertainties that are subject to change at any time, including but not limited to statements about elites' expectations regarding forward operating results.

Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws and represent management's current expectations. Actual

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.